Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04681677 · ClinicalTrials.gov registry record · Phase 2
Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab
A Phase 2 study, sponsored by Xoft.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT04681677 is a Phase 2 study that was terminated before completion, run by Xoft. The registered enrollment target is 12 participants.
The verdict
NCT04681677, a Phase 2 study, was terminated before completion, sponsored by Xoft.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this trial is to assess the overall survival of patients treated with the Xoft Axxent eBx System and post-radiation adjuvant Bevacizumab for single-fraction IORT following maximal neurosurgical resection of recurrent glioblastoma. A historical comparison will be made to the results of the EBRT + Bevacizumab arm of RTOG 1205.
Interventions
- DRUG Bevacizumab
- RADIATION Radiation: Intra-operative Radiation Therapy - IORT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-11-02 |
| Est. Completion | 2024-04-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04681677
The ClinicalTrials.gov registry entry for NCT04681677 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xoft, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT04681677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04681677 about?
NCT04681677 is a clinical study titled "Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab". The purpose of this trial is to assess the overall survival of patients treated with the Xoft Axxent eBx System and post-radiation adjuvant Bevacizumab for single-fraction IORT following maximal neurosurgical resection of recurrent glioblastoma. A historical comparison will be made to the results of...
What is the current status of trial NCT04681677?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-11-02. Estimated completion is 2024-04-24.
What interventions are being tested in trial NCT04681677?
The interventions under investigation include: Bevacizumab (DRUG), Radiation: Intra-operative Radiation Therapy - IORT (RADIATION).
Who is sponsoring clinical trial NCT04681677?
This trial is sponsored by Xoft, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.